Core Viewpoint - North Chip Life Technology Co., Ltd. has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking the first successful listing of an innovative medical device company under the "fifth set of standards" [1][2] Company Overview - North Chip Life focuses on the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, with 17 approved and in-development products as of September 30, 2025 [1][3] - The company was founded in December 2015 by Song Liang, who has over 18 years of experience in advanced medical imaging technology and cardiovascular interventional device development [2][3] Financial Performance - The company has experienced significant revenue growth, with projected revenues of 520 million to 560 million yuan in 2025, representing a year-on-year increase of 64.24% to 76.88% [5] - The net profit for 2025 is expected to be between 78 million and 88 million yuan, marking a turnaround from previous losses [5] - The company raised a total of 999 million yuan in its IPO, with a net amount of 899 million yuan allocated primarily for the construction of an interventional medical device industrial base and R&D [5] Product Development and Market Position - North Chip Life has launched 11 products to the market and has 6 products in development, with its core IVUS and FFR systems having received special review and approval from national authorities [3][4] - The IVUS system is the first domestically approved 60MHz high-speed IVUS product and has captured a significant market share, while the FFR system holds a 30.6% share of the domestic market [4][5] R&D Investment - The company has consistently increased its R&D investment, totaling 389 million yuan over the past three years, with a workforce of 100 R&D personnel, over 40% of whom hold advanced degrees [3][5] Market Trends and Growth Potential - The domestic market for IVUS is expected to grow significantly, with projections indicating a compound annual growth rate of approximately 19.4% from 2024 to 2030 [8] - The overall market for precision-guided percutaneous coronary intervention (PCI) is anticipated to grow from 2.04 billion yuan in 2022 to 9.42 billion yuan by 2030, with IVUS and FFR systems expected to dominate this market [8] Competitive Landscape - North Chip Life faces competition from established international firms and other domestic manufacturers in the IVUS and FFR markets, which may impact its market share and pricing strategies [7][8] - The company is also subject to pressures from national procurement policies that could affect pricing and market dynamics [7][8]
北芯生命正式登陆科创板 心血管精准诊疗格局加速重构